Literature DB >> 1325432

Alteration of type II regulatory subunit of cAMP-dependent protein kinase in human cisplatin-resistant cells as a basis of collateral sensitivity to 8-chloro-cAMP.

K Nishio1, T Morikage, N Kubota, T Ohmori, Y Takeda, Y Fujiwara, K Miki, K Abe, N Saijo.   

Abstract

A cyclic adenosine 3',5'-monophosphate (cAMP) analogue, 8-chloro-cAMP (8-Cl-cAMP), had a collateral growth-inhibitory effect on a cis-diamminedichloroplatinum(II) (CDDP)-resistant human cancer cell lines (PC-14/CDDP). The non-selective analogues dibutyryl-cAMP, 8-bromo-cAMP and forskolin, which are cAMP agonists, showed far less cytotoxicity than 8-Cl-cAMP in both cell lines. There was no significant difference in cAMP content between PC-14 and PC-14/CDDP. Because 8-Cl-cAMP has been shown to bind selectively to the site I receptor of the type II regulatory subunit (RII) of cAMP-dependent protein kinase, we determined the level of expression of regulatory subunits in PC-14 and PC-14/CDDP cells by photoaffinity labeling. PC-14/CDDP cells had a higher RII level, low site I receptor of type I regulatory subunit (RI) level, and a lower RI/RII ratio than the parental PC-14 cells. Exposure to 8-Cl-cAMP increased the RI and RII level in PC-14/CDDP cells in dose- and time-dependent manners. On the other hand, in parental PC-14 cells, RII was not detected and the levels of RI and RII were not increased by exposure to 8-Cl-cAMP. These results suggested that the change in RI and/or RII levels caused by 8-Cl-cAMP was correlated with 8-Cl-cAMP-induced growth inhibition and that the collateral sensitivity to 8-Cl-cAMP in CDDP-resistant cells was due to the increased RII level. Our results suggest that 8-Cl-cAMP can be used in combination with CDDP and that measurement of RI and RII levels and/or the RI/RII ratio is a useful tool to predict CDDP sensitivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325432      PMCID: PMC5918934          DOI: 10.1111/j.1349-7006.1992.tb01976.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


m‐diamminedichloro‐platinum(II) cyclic adenosine 3′,5′‐monophosphate 8‐chloro‐cAMP site I receptor of type I regulatory submit site I receptor of type II regulatory subunit phosphate‐buffered saline fetal bovine serum 5′‐cyclic [32P]monophosphate 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide polyacrylamide gel 8‐bromo‐cAMP molecular weight photo‐stimulated luminescence
  32 in total

1.  Comparison of adenosine 3':5'-monophosphate-dependent protein kinases from rabbit skeletal and bovine heart muscle.

Authors:  F Hofmann; J A Beavo; P J Bechtel; E G Krebs
Journal:  J Biol Chem       Date:  1975-10-10       Impact factor: 5.157

2.  Photoaffinity labeling of a protein kinase from bovine brain with 8-azidoadenosine 3',5'-monophosphate.

Authors:  A H Pomerantz; S A Rudolph; B E Haley; P Greengard
Journal:  Biochemistry       Date:  1975-08-26       Impact factor: 3.162

3.  Adenylate cyclase and protein phosphokinase activities in human thyroid. Comparison of normal glands, hyperfunctional nodules and carcinomas.

Authors:  G Sand; A Jortay; R Pochet; J E Dumont
Journal:  Eur J Cancer       Date:  1976-06       Impact factor: 9.162

Review 4.  Type I cyclic AMP-dependent protein kinase as a positive effector of growth.

Authors:  D H Russell
Journal:  Adv Cyclic Nucleotide Res       Date:  1978

5.  Cyclic nucleotide-dependent protein kinases. IV. Widespread occurrence of adenosine 3',5'-monophosphate-dependent protein kinase in various tissues and phyla of the animal kingdom.

Authors:  J F Kuo; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1969-12       Impact factor: 11.205

Review 6.  Cyclic nucleotides in human cerebral tumors: role of the protein kinase system.

Authors:  M Trabucchi; N Canal; L Frattola
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1984

Review 7.  Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy.

Authors:  Y S Cho-Chung
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

8.  Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate.

Authors:  S Ally; T Clair; D Katsaros; G Tortora; H Yokozaki; R A Finch; T L Avery; Y S Cho-Chung
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701

9.  Adenosine 3':5'-cyclic monophosphate-binding proteins in bovine and rat tissues.

Authors:  P H Sugden; J D Corbin
Journal:  Biochem J       Date:  1976-11       Impact factor: 3.857

10.  Concentrations of cyclic AMP-dependent protein kinase subunits in various tissues.

Authors:  F Hofmann; P J Bechtel; E G Krebs
Journal:  J Biol Chem       Date:  1977-02-25       Impact factor: 5.157

View more
  3 in total

1.  An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Authors:  Nicholas Pulliam; Fang Fang; Ali R Ozes; Jessica Tang; Adeoluwa Adewuyi; Harold Keer; John Lyons; Stephen B Baylin; Daniela Matei; Harikrishna Nakshatri; Feyruz V Rassool; Kathy D Miller; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2018-04-03       Impact factor: 12.531

2.  Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP.

Authors:  A G Bosanquet; A R Burlton; P B Bell; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Reversal of radiation-induced cisplatin resistance in murine fibrosarcoma cells by selective modulation of the cyclic GMP-dependent transduction pathway.

Authors:  H Eichholtz-Wirth
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.